COVID-19 vaccine side effect: age and gender disparity in adverse effects following the first dose of AstraZeneca COVID-19 vaccine among the vaccinated population in Eastern Ethiopia: a community-based study

Astawus Alemayehu1,2, Abebaw Demissie1,3, Mohammed Yusuf1,4, Yasin Abdullahi5, Remzia Abdulwehab2,6, Lemessa Oljira6 and Dereje Feleke7

Abstract

Objective: The pandemic of coronavirus disease 2019 (COVID-19) is a major threat to community health, and vaccinations are a safe and effective way to reduce disease loads around the world. This study aimed to assess the age and gender disparity in adverse effects following the first dose of the AstraZeneca COVID-19 vaccine among the vaccinated population in Eastern Ethiopia.

Methods: A community-based cross-sectional study design was conducted among 832 randomly selected individuals from December 1st to 20th, 2021, in eastern Ethiopia. Data were collected by face-to-face interviews using a pretested structured questionnaire. Data were analyzed using the SPSS V26. Descriptive summary statistics were done. A chi-square test statistic was computed to assess the difference in adverse effects between age groups and both genders.

Result: Out of 832 study participants who had taken the first dose of AstraZeneca vaccine, 96.3% of them felt at least one adverse effect. The magnitude of adverse reactions was higher among male participants. The reported adverse reactions were significantly higher in the age group of 50–60 years with comorbidity than those of <50 and >60 years of age.

Conclusion: Overall, there is a significant age and gender difference in adverse effects following the first dose of the AstraZeneca COVID-19 vaccine. In addition, adverse reactions were higher among people with comorbidity in the age group of 50–60 years. The Harari Regional Health Bureau should provide training for frontline healthcare workers on early recognition and response to adverse effects of the COVID-19 vaccine. In addition, information and education should be provided to the community as a whole regarding recognition and the appropriate measures to be taken.

Keywords
COVID-19 vaccine, adverse effects, gender disparity, age disparity

Date received: 15 January 2022; accepted: 2 June 2022

1Department of Nursing, Rift Valley University, Harar, Ethiopia
2Department of Public Health, Harar Health Science College, Harar, Ethiopia
3Department of Anesthesia, Harar Health Science College, Harar, Ethiopia
4Department of Nursing, Harar Health Science College, Harar, Ethiopia
5Department of Management, Harar Health Science College, Harar, Ethiopia
6School of Public Health, College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia
7Department of Health Informatics, Harar Health Science College, Harar, Ethiopia

Corresponding author:
Astawus Alemayehu, Department of Public Health, Harar Health Science College, Harar City, Harari Regional State 228, Ethiopia.
Email: astawusalemayehu@gmail.com
Introduction

The pandemic of coronavirus disease is a major threat to community health and has had a substantial impact on various aspects of society.\(^1\) Million cases of illness and deaths had been confirmed.\(^2\) In addition to its health consequences, coronavirus disease 2019 (COVID-19) has a major economic impact that should not be neglected.\(^3\)

Given the disease’s worrisome rate of spread and the enormous expense of depending solely on non-pharmaceutical measures,\(^4\) the world urgently requires safe and effective vaccines to protect vulnerable populations and restore people’s lives to their original state.\(^5\) Vaccinations are a safe and effective way to reduce disease loads around the world.\(^6\) Vaccination is widely acknowledged as having made the highest impact on global health of any human effort.\(^7\)

Public concerns about vaccine safety and side effects may play a role in vaccine safety as scientists throughout the world work on a potential COVID-19 vaccine.\(^1\) Several safe and effective vaccines prevent people from getting seriously ill or dying from the COVID-19 infection.\(^8\) One of these is the AstraZeneca vaccine which protects people from the extremely risky dangers of COVID-19, such as death, hospitalization, and severe sickness.\(^9\)

Vaccines, like all drugs, can have negative effects. The majority of these are mild to moderate in nature and are just temporary.\(^10\) Studies have reported COVID-19 vaccines side effects including severe reactions, such as deep vein thrombosis, transverse myelitis, and even anaphylactic shock.\(^11,12\) Center for Disease Control and Prevention (CDC) and other studies had reported COVID-19 vaccination side effects like local reactions such as pain, swelling, and redness at the injection site; as well as systemic effects including joint pain, tiredness, back pain, muscle pain, headache, chills, fever, and nausea.\(^13-17\)

However, the United Kingdom Health Security Agency advises that those who have received the first dose of the AstraZeneca vaccination and have experienced no major side effects should be administered the second dosage to finish the course.\(^10\) Potential adverse effects of AstraZeneca include rash, swelling of face, lips, and throat, feeling light-headed, changes in heartbeat, wheezing, shortness of breath, stomach pain, nausea, and vomiting.\(^18\)

Some preliminary studies have indicated that there are gender and age differences in the manifestation of COVID-19 vaccination side effects.\(^19\) Gender differences have been observed in the severe acute respiratory syndrome coronavirus-2 infectivity and the frequency of severity of COVID-19.\(^20\) In addition, there is a gender difference in the frequency of adverse effects after COVID-19 vaccination.\(^21\)

There are no studies that addressed age and gender disparity in adverse effects following the first dose of the AstraZeneca COVID-19 vaccine among the vaccinated population in Eastern Ethiopia.

Method and materials

Study area and period

The study was carried out in the Harari region from December 1st to 20th, 2021, in eastern Ethiopia. The total estimated population of Harar was 246,000, and approximately 150,060 (61%) of the population live in urban areas. There are nine districts in total. Of these, six of them are in urban areas, and the rest of them are in rural areas. The total dose of AstraZeneca COVID-19 vaccine administered in the regional states of Harari as of December 10, 2021, was 26,800, among these 16,130 and 10,670 were from urban and rural, respectively. This study assessed age and gender disparity in adverse effects following the first dose of the AstraZeneca COVID-19 vaccine among the vaccinated population in Harar, Eastern Ethiopia, in 2021.

Study design and population

A community-based cross-sectional study design was used. Our source population was the whole population who had taken the first dose of the AstraZeneca COVID-19 vaccine in Harari Regional State. The study population consists of all participants randomly chosen from each stratum.

Sample size determination and sampling technique

To calculate the required samples, we used a single proportion formula with a 95% confidence interval, a 5% margin of error, and the assumption of a 50% proportion. Then, it was multiplied by 2 (design effects), and finally, a 10% non-response rate was added.

\[
\begin{align*}
\text{Sample size (n)} &= \frac{Z_{\alpha/2}^2 p(1-p)}{d^2} \\
&= \frac{(1.96)^2 \times 0.05 \times 0.5}{0.05^2} \\
&= 384, 384 \times 2 = 768, \text{ by adding 10% (77) } \approx 845
\end{align*}
\]

The complete list of individuals who had taken the first dose of the AstraZeneca COVID-19 vaccine was taken from the Regional Health Bureau. The participant’s home addresses and telephone numbers were taken from vaccine registry books to trace and recruit subjects. Then study participants who volunteered during the data collection period to engage in the study were included. The study participants were selected using a stratified sampling technique, which was classified into two strata based on their residence areas (urban and rural). The total sample size was proportionally allocated for urban (16,130) and rural (10,670) populations.
who had taken the AstraZeneca COVID-19 vaccine, which is 509 for urban and 336 for rural. Then, the study participants were randomly selected from each stratum.

**Data collection tool and procedure**

Data were collected using face-to-face interviews with a pre-tested structured questionnaire. The questionnaire was prepared in the English language and translated into the local languages (Afan Oromo and Amharic), which was adapted, after reviewing relevant literature and the World Health Organization COVID-19 vaccine report. The questionnaire consisted of two parts: the first part was sociodemographic-related variables (age, sex, marital status, occupational status, level of education, average monthly income, and family members), and the second part included COVID-19 vaccine-related variables (adverse effects, onset of symptoms, duration of adverse effect, and types of treatment taken) as an outcome variable. Data were collected by ten 4th-year public health students.

**Data quality control**

To assure the quality of the data, a 3-day training was given for data collectors on how to interview and collect data. A pretest was done on 5% of the questionnaire in Fedis district. Close supervision of the data collectors was conducted by the authors. The reliability of the questionnaire was calculated, and the value of Cronbach’s alpha was found to be 0.769. The collected data were checked both in the field, at the end of each day after data collection, and before data entry for completeness and missing values. Double data entry was performed.

**Statistical analysis**

The data were examined for completeness, clarity, and consistency after it was collected. The data were coded and entered into Epidata v.3.0, and SPSS v.26 was used to analyze it. To summarize the results, summary statistics were produced in the form of percentages. A chi-square test analysis was computed to assess the association between the dependent and independent variables and the difference in adverse effects between age groups and both genders. Then, those variables with a p value <0.05 were declared as having a statistically significant association. We have used the STROBE checklist for cross-sectional study design for writing the finding of the study.

**Operational definition**

**Adverse effects:** If the participants experienced at least one of the following symptoms (local pain, local swelling, redness at injection site, fatigue, fever, headache, muscle pain chills, and nausea) after taking the AstraZeneca COVID-19 vaccine.

**Ethical consideration**

The protocol of this study for the subject recruitment process and participation in the study adhered to the Declaration of Helsinki’s guidelines and an ethical approval letter was obtained from the Harar Health Science College Institutional Health Research Ethics Committee with reference No. IHREC 02/595/254/2/14.

**Results**

**Sociodemographic characteristics of study participants**

A total of 832 study participants participated in the study, with a response rate of 98.5%. The majority, 75%, of them were between 50 and 60 years of age, with a mean age of 56.2 (±8.4SD). Fifty-eight percent of them were married, and 61% had a monthly income of less than 5000 Ethiopian Birr (ETB) on average (Table 1).

**Prevalence of adverse effects following the first dose of AstraZeneca COVID-19 vaccine**

Out of 832 study participants who had taken the first dose of AstraZeneca vaccine, 801 (96.3%) of them felt at least one adverse effect. Of these, the most commonly reported adverse effects were local pain, fatigue, fever, and headache, at 80.4%, 70.7%, 57.1%, and 44.3%, respectively, and less commonly or rarely reported adverse reactions were nausea (2.9%) and vomiting (1.9%) (Table 2).

**Gender disparities in adverse effects following the first dose of AstraZeneca COVID-19 vaccine**

The severity of adverse reactions was slightly higher in male individuals overall. Out of 389 male study participants, 98.2% of them had felt at least one adverse effect, whereas of a total of 443 females, 94.6% had felt adverse effects ($\chi^2$-test, $p=0.006$). There is a significant difference between males and females in adverse effects following the first dose of the AstraZeneca COVID-19 vaccine. Regarding the reports of adverse reactions, local pain and local swelling were significantly higher among males than females, which was local pain: 80.7% for males, 74.5% for females, and local swelling: 33.9% for males, 27.5% for females, $p=0.046$. The analysis of chi-square revealed that there is a significant gender difference in adverse effects (Table 2).

**Adverse effects duration and measures taken to get relief based on gender**

Regarding the reported adverse effects, overall, 57.6% and 25.7% of adverse effect symptoms started within 12–17h and 6–11h, respectively, after taking the vaccine. The majority, 62.3%, of reported adverse effects lasted for 2 days.
Among the participants, early onset of symptoms of adverse effects was reported among males more than females. On the other hand, late onset of symptoms was observed among females than males (Table 3). Among the total of 489 participants who had taken analgesics for relieving symptoms, 52.1% were males (Figure 1).

**Table 1.** Sociodemographic characteristics of study participants who had taken the first dose of AstraZeneca COVID-19 vaccine in Harar, Eastern Ethiopia, 2021.

| Sociodemographic variables | Urban (n = 509) | Rural (n = 323) | Total (N = 832) | Percentage (%) |
|----------------------------|----------------|----------------|----------------|----------------|
| Age in years               |                |                |                |                |
| <50                        | 46 (38.7%)     | 73 (61.3%)     | 119            | 14.3           |
| 50–60                      | 425 (67.5%)    | 205 (32.5%)    | 630            | 75.7           |
| >60                        | 38 (45.8%)     | 45 (54.2%)     | 83             | 10             |
| Sex                        |                |                |                |                |
| Male                       | 274 (58.5%)    | 194 (41.4%)    | 468            | 56.3           |
| Female                     | 235 (64.6%)    | 129 (35.4%)    | 364            | 43.7           |
| Marital status             |                |                |                |                |
| Single                     | 197 (68.4%)    | 91 (31.6%)     | 288            | 34.6           |
| Married                    | 278 (57.2%)    | 208 (42.8%)    | 486            | 58.4           |
| Divorced                   | 19 (63.3%)     | 11 (36.7%)     | 30             | 3.6            |
| Widow                      | 11 (64.7%)     | 6 (35.3%)      | 17             | 2              |
| Separated                  | 4 (36.4%)      | 7 (63.6%)      | 11             | 1.3            |
| Occupational status        |                |                |                |                |
| Housewife                  | 92 (60.5%)     | 60 (39.5%)     | 152            | 18.3           |
| Marchant                   | 161 (76.3%)    | 50 (23.7%)     | 211            | 25.4           |
| Civil servant              | 157 (78.9%)    | 42 (21.1%)     | 199            | 23.9           |
| Labor work                 | 87 (60.8%)     | 56 (39.2%)     | 143            | 17.2           |
| NGOs                       | 13 (9.8%)      | 120 (90.2%)    | 133            | 16             |
| Driver                     | 20 (100%)      | 0 (0.0%)       | 20             | 2.4            |
| Level of educational       |                |                |                |                |
| Unable to read and write   | 21 (18.9%)     | 90 (81.1%)     | 111            | 13.3           |
| Primary education          | 125 (69.4%)    | 55 (30.6%)     | 180            | 21.6           |
| Secondary education        | 141 (61.8%)    | 87 (38.2%)     | 228            | 27.4           |
| Above secondary education  | 222 (70.9%)    | 91 (29.1%)     | 313            | 37.6           |
| Average monthly income     |                |                |                |                |
| <5000 ETB                  | 304 (59.1%)    | 210 (40.8%)    | 514            | 61.8           |
| 5000–9999 ETB              | 163 (65.5%)    | 86 (34.5%)     | 249            | 30             |
| 10000–14999 ETB            | 32 (68.1%)     | 15 (31.9%)     | 47             | 5.6            |
| ⩾15,000 ETB               | 10 (45.4%)     | 12 (54.5%)     | 22             | 2.6            |
| Family size                |                |                |                |                |
| <5                        | 303 (64.2%)    | 169 (35.8%)    | 472            | 56.7           |
| 5–9                       | 188 (58.6%)    | 133 (41.4%)    | 321            | 38.6           |
| ⩾10                       | 18 (46%)       | 21 (53.8%)     | 39             | 4.7            |
| Had chronic disease        |                |                |                |                |
| Yes                       | 436 (64.2%)    | 243 (35.8%)    | 679            | 81.6           |
| No                        | 73 (47.7%)     | 80 (52.3%)     | 153            | 18.4           |
| Types of chronic disease   |                |                |                |                |
| Hypertension               | 177 (64.1%)    | 99 (35.9%)     | 276            | 40.6           |
| Diabetes                   | 157 (66.2%)    | 80 (33.8%)     | 237            | 34.9           |
| Asthma                     | 2 (40%)        | 3 (60%)        | 5              | 0.7            |
| Both hypertension and diabetes | 91 (61.9%)   | 56 (38.1%)     | 147            | 21.6           |
| Heart disease              | 9 (64.3%)      | 5 (35.7%)      | 14             | 2.1            |

COVID-19, coronavirus disease 2019; NGOs, non-government organizations.

Among the participants, early onset of symptoms of adverse effects was reported among males more than females. On the other hand, late onset of symptoms was observed among females than males (Table 3). Among the total of 489 participants who had taken analgesics for relieving symptoms, 52.1% were males (Figure 1).

**Age disparities in adverse effects following the first dose of AstraZeneca COVID-19 vaccine**

Overall, the prevalence of reported adverse reactions was significantly higher in the age group of 50–60 years than <50 and >60 years, which was 89.5%, 99.7%, and 70.1%
with \( p < 0.001 \), respectively. Among the reported adverse reactions, headaches (44.5\%, \( p = 0.048 \)), fever (56.8\%, \( p = 0.377 \)), and local pain (80.7\%, \( p < 0.001 \)) were more commonly reported in the age group of 50–60 years. The chi-square analysis indicated that these adverse reactions were statistically significant differences between the age groups (Table 4).

### Table 2. Adverse effects of AstraZeneca COVID-19 vaccine reported by participants who had taken the first dose vaccine and disparities in gender, Harar Eastern Ethiopia, 2021.

| Adverse reaction                  | Total (N=832) | Male (n=389) | Female (n=443) | \( \chi^2 \)-test | \( p \)-Value |
|-----------------------------------|---------------|--------------|----------------|------------------|--------------|
| Had any adverse effect            | 801 (96.3)    | 382 (98.2)   | 419 (94.6)     | 0.006*           |              |
| Headache                          | 355 (44.3)    | 161 (41.4)   | 194 (43.8)     | 0.484            |              |
| Fever                             | 457 (57.1)    | 220 (56.6)   | 237 (53.5)     | 0.377            |              |
| Local pain                        | 644 (80.4)    | 314 (80.7)   | 330 (74.5)     | 0.032*           |              |
| Local swelling                    | 254 (31.7)    | 132 (33.9)   | 122 (27.5)     | 0.046*           |              |
| Fatigue                           | 566 (70.7)    | 264 (67.8)   | 302 (68.2)     | 0.925            |              |
| Chills                            | 305 (38.1)    | 134 (34.4)   | 171 (38.6)     | 0.215            |              |
| Nausea                            | 23 (2.9)      | 14 (3.6)     | 9 (2)          | 0.169            |              |
| Vomiting                          | 13 (1.9)      | 9 (2.3)      | 4 (0.9)        | 0.102            |              |

\( n \), sub-group sample; \( \chi^2 \), chi-square; "Bold number, statistically significant at \( p \) value < 0.05. COVID-19, coronavirus disease 2019.

### Table 3. Reported adverse effects illness duration and measures taken to get relief by their gender in Harar population, Eastern Ethiopia, 2021.

| Illness duration and measures taken | Male (n=382) | Female (n=419) | n=801 (n (%)) |
|------------------------------------|--------------|----------------|---------------|
| When did symptoms start             |              |                |               |
| <6 h                               | 20 (5.2%)    | 17 (4.8%)      | 37 (4.6%)     |
| 6–11 h                             | 105 (27.5%)  | 101 (24.1%)    | 206 (25.7%)   |
| 12–17 h                            | 227 (59.4%)  | 234 (55.8%)    | 461 (57.6%)   |
| 18–23 h                            | 27 (7.1%)    | 56 (13.4%)     | 83 (10.4%)    |
| >24 h                              | 3 (0.8%)     | 11 (2.6%)      | 14 (1.7%)     |
| Adverse effects lasted              |              |                |               |
| 1 day                              | 41 (10.7%)   | 38 (9.1%)      | 79 (9.9%)     |
| 2 days                             | 224 (58.6%)  | 275 (65.6%)    | 499 (62.3%)   |
| 3 days and above                   | 117 (30.6%)  | 106 (25.3%)    | 223 (27.8%)   |
| Take any form of treatment          |              |                |               |
| Yes                                | 377 (98.7%)  | 412 (98.3%)    | 789 (98.5%)   |
| No                                 | 5 (1.3%)     | 7 (1.7%)       | 12 (1.5%)     |

with \( p < 0.001 \), respectively. Among the reported adverse reactions, headaches (44.5\%, \( p = 0.048 \)), fever (56.8\%, \( p = 0.377 \)), and local pain (80.7\%, \( p < 0.001 \)) were more commonly reported in the age group of 50–60 years. The chi-square analysis indicated that these adverse reactions were statistically significant differences between the age groups (Table 4).

### Adverse effects duration and measures taken to get relief based on age

Regarding the reported adverse effects, overall, 57.6\% and 25.7\% of adverse effect symptoms started within 12–17 h and 6–11 h, respectively, after taking the vaccine. Among these, majority of them were found between 50 and 60 years of age. The majority, 62.3\%, of reported adverse effects lasted for 2 days. People with age <50 years have not shown adverse symptoms during the first 11 h, whereas the majority of participants between 50 and 60 years of age started to feel symptoms within the first 11 h (Table 5). Among the total of 489 participants who had taken analgesics for relieving symptoms, 83.2\% were found in the age group of 50–60 years (Figure 2).

### Discussion

This study was the first study conducted in Ethiopia that tried to assess gender and age disparities in adverse effects following the AstraZeneca COVID-19 vaccine among the population in Eastern Ethiopia. In the study, commonly reported adverse effects by participants were local pain at the injection site, fatigue, fever, and headache.

Overall, 96.3\% of the study participants felt at least one adverse effect after receiving the AstraZeneca COVID-19 vaccine. This finding was consistent with similar studies from Kabul, Afghanistan,\(^{23}\) where (93.5\%) and Jordan\(^{24}\) (89.9\%) participants reported at least one adverse effect following the first dose of AstraZeneca COVID-19 vaccine.
vaccination. However, this finding is higher than studies from Debre Markos, Ethiopia,\textsuperscript{25} Turkey,\textsuperscript{26} and Bangladesh\textsuperscript{27} where 75%, 62.5%, and 55% of participants reported at least one adverse reaction following vaccination, respectively. These observed variations could be due to differences in study population demographic data such as age, race-based pain threshold, and psychological differences in symptoms reporting behavior.

In our study, fatigue, headache, pain at the injection site, and fever were adverse effects commonly reported by participants. This is similar to an experimental study on the ChAdOx1 nCoV-19 vaccine, which identified fatigue (53.1%), headache (52.6%), pain at the site of injection (54.2%), and tenderness at the site of injection (63.7%) as frequently reported adverse effects. Furthermore, this is similar to the adverse reactions reported after taking the AstraZeneca nCoV-19 vaccine in Debre Markos, Ethiopia,\textsuperscript{25} Turkey,\textsuperscript{26} Afghanistan,\textsuperscript{23} and Bangladesh.\textsuperscript{27}

In this study, gender disparity was observed in reporting side effects following the first dose of the AstraZeneca vaccine and the magnitude of adverse reactions was slightly higher in male participants than females. This is congruent

---

**Table 4.** Adverse effects of AstraZeneca COVID-19 vaccine reported by participants who had taken the first dose vaccine and disparities in age, Harar Eastern Ethiopia, 2021.

| Adverse reaction | Total (N=832) | Age < 50 (n=86) | Age 50–60 (n=679) | Age > 60 (n=67) | $\chi^2$-test | p Value |
|------------------|---------------|-----------------|-------------------|----------------|--------------|---------|
| Had any adverse effect | 801 (96.3) | 77 (89.5) | 677 (99.7) | 47 (70.1) | <0.001* | |
| Headache | 355 (44.3) | 33 (38.4) | 302 (44.5) | 20 (29.8) | 0.048* | |
| Fever | 457 (57.1) | 45 (52.3) | 386 (56.8) | 26 (38.8) | 0.016* | |
| Local pain | 644 (80.4) | 60 (69.8) | 548 (80.7) | 36 (53.7) | <0.001* | |
| Local swelling | 254 (31.7) | 29 (33.7) | 212 (31.2) | 13 (19.4) | 0.107 | |
| Fatigue | 566 (70.7) | 58 (67.4) | 470 (69.2) | 38 (56.7) | 0.111 | |
| Chills | 305 (38.1) | 29 (33.7) | 251 (37) | 25 (37.3) | 0.835 | |
| Nausea | 23 (2.9) | 2 (2.3) | 21 (3.1) | 0 (0.0) | 0.326 | |
| Vomiting | 13 (1.9) | 2 (2.3) | 11 (1.6) | 0 (0.0) | 0.496 | |

COVID-19, coronavirus disease 2019; n, sub-group sample; $\chi^2$, chi-square. * Bold indicates statistically significant at p < .05.
with a study from China where higher proportions of males reported adverse effects than females. On the contrary, other similar studies from Saudi Arabia, Turkey, and Bangladesh have reported that a higher percentage of female participants suffered from post-vaccination side effects compared to males.

In our study, the observed gender disparities in adverse effects following COVID-19 vaccines might be related to the different immune responses between gender. Immunological responses to antigens differ between males and females, as do innate and adaptive immune responses. When males are compared to females, the cellular immunological response of the particular immune system is suppressed.

Overall, the prevalence of reported adverse reactions was significantly higher among 50–60 years age group individuals than among people <50 years and >60 years of age. However, other similar studies reported variable results related to age disparity on side effects following COVID-19 vaccination. For instance, a study from China indicated that older people greater than 65 years are more likely to have adverse reactions than those between 18 and 64 years. On the other hand, an Afghanistan study reported that the
frequency of adverse reactions was higher in participants aged 40 years or less than in older participants. Similarly, studies conducted in Bangladesh\textsuperscript{27} and Turkey\textsuperscript{26} revealed that corona vaccine side effects were found to be significantly more prevalent in the younger population. This could be due to different immune responses to antigens, differences in innate and adaptive immune responses in different age groups,\textsuperscript{31,32} and host race or ethnicity.\textsuperscript{33}

**Limitation of the study**

The study used a cross-sectional study design. Therefore, there is a temporal issue and also more prone to recall bias. There is a lack of similar studies for comparison. As the study was addressing side effects after the first dose, information regarding adverse effects after the second dose may be limited.

**Conclusion**

Overall, 96.3\% of the study participants felt at least one adverse effect after receiving the AstraZeneca COVID-19 vaccine. The magnitude of COVID-19 vaccine adverse effects was higher among male participants and those in the age group 50–60 years with comorbidity.

The government should provide training for frontline healthcare workers on early recognition and response to adverse effects of the COVID-19 vaccine as per the recommendation of the CDC. In addition, information and education should be provided to the community as a whole regarding recognition and the appropriate measures to be taken.

**Acknowledgements**

First of all, we would like to express our thanks to the almighty God. We would also like to extend our gratitude to the study participants who were involved in the study. Finally, we thank Mrs. Ikram Mohammed for editing the language and grammatical flow.

**Author contributions**

AA, MY, and AD participated in the study from inception to design, acquisition of data, analysis, and interpretation of the results. LO, YA, RA, and DF participated in the methods, analysis, interpretation, and writing of the manuscript of the results. Finally, all authors approved the manuscript for publication and the journal to which it has been submitted.

**Data availability**

At any time, the corresponding author provides an additional resource on request.

**Declaration of conflicting interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Ethics approval**

The protocol of this study for subject recruitment process and participation in the study adhered to the Declaration of Helsinki’s guidelines and an ethical approval letter was obtained from Harar Health Science College Institutional Health Research Ethics Committee with reference No. IHREC 02/595/254/2/14.

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Harar Health Science College for the study in exchange for the authorship and publication of this article.

**Consent to participate**

Oral informed consent was obtained from participants before collecting data. All participants provided their consent prior to participating in the study. Participation was completely voluntary, and the participants were free to withdraw from the study at any time without any consequence. Confidentiality of all information has been maintained. This form of obtaining consent was approved by the IEC.

**ORCID iDs**

Astawus Alemayehu : https://orcid.org/0000-0003-1384-7123
Remzia Abdulwehab : https://orcid.org/0000-0001-7465-5622

**Trial registration**

Not applicable.

**Supplemental material**

Supplemental material for this article is available online.

**References**

1. CDC. Certain medical conditions and risk for severe COVID-19 illness, https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html (2019, accessed 20 December 2021).
2. Worldometer C. Coronavirus Worldometer | 15 countries with the highest number of cases, and deaths due to the Covid-19 pandemic, https://www.deccanherald.com/international/coronavirus-updates-cases-deaths-country-wise-worldometers-info-data-covid-19-834531.html#1 (2021, accessed 16 December 2021).
3. Africa W. Ethiopia introduces COVID-19 vaccine in a national launching ceremony, https://www.afro.who.int/news/ethiopia-introduces-covid-19-vaccine-national-launching-ceremony (2021, accessed 16 December 2021).
4. Flaxman S, Mishra S, Gandy A, et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. *Nature* 2020; 584: 257–261.
5. Haidere MF, Ratan ZA, Nowroz S, et al. COVID-19 vaccine: critical questions with complicated answers. *Biomol Ther (Seoul)* 2021; 29: 1–10.
6. Sultana J, Mazzaglia G, Lusi N, et al. Potential effects of vaccinations on the prevention of COVID-19: rationale, clinical evidence, risks, and public health considerations. *Expert Rev Vaccines* 2020; 19: 919–936.
7. Greenwood B. The contribution of vaccination to global health: past, present, and future. Philos Trans R Soc Lond B Biol Sci 2014; 369: 20130433.

8. WHO. COVID-19 advice for the public: getting vaccinated. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice (2021, accessed 16 December 2021).

9. WHO. The Oxford/AstraZeneca COVID-19 vaccine: what you need to know, https://www.who.int/news-room/feature-stories/detail/the-oxford-astrazeneca-covid-19-vaccine-what-you-need-to-know (2021, accessed 16 December 2021).

10. England PH. Guidance | Worried about having your second dose of AstraZeneca vaccination? https://www.gov.uk/government/publications/covid-19-vaccination-worried-about-having-your-second-dose-of-astrazeneca?view=print (2021, accessed 16 December 2021).

11. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021; 397: 99–111.

12. Carli G, Nichele I, Ruggeri M, et al. Deep vein thrombosis (DVT) occurring shortly after the second dose of mRNA SARS-CoV-2 vaccine. Intern Emerg Med 2021; 16: 803–804.

13. Song JE, Oh GB, Park HK, et al. Survey of adverse events after the first dose of the ChAdOx1 nCoV-19 vaccine: a single-center experience in Korea. Infect Chemother 2021; 53: 557–561.

14. Kim SH, Wi YM, Yun SY, et al. Adverse events in healthcare workers after the first dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 vaccination: a single center experience. J Korean Med Sci 2021; 36: e107. 2021O412.

15. Centers for Disease Control and Prevention. Possible side effects after getting a COVID-19 vaccine, https://www.cdc.gov/coronavirus/2019-ncov/vaccines/expect/after.html (2021, accessed 20 December 2021).

16. Klugar M, Riad A, Mekhemar M, et al. Side effects of mRNA-based and viral vector-based COVID-19 vaccines among German healthcare workers. Biology (Basel) 2021; 10: 752.

17. Riad A, Pokorná A, Mekhemar M, et al. Safety of ChAdOx1 nCoV-19 vaccine: independent evidence from two EU states. Vaccines (Basel) 2021; 9: 673.

18. Graffigna G, Palamenghi L, Boccia S, et al. Relationship between citizens’ health engagement and intention to take the COVID-19 vaccine in Italy: a mediation analysis. Vaccines 2020; 8: 576.

19. Gee J, Marquez P, Su J, et al. First month of COVID-19 vaccine safety monitoring—United States, December 14, 2020–January 13, 2021. MMWR Morb Mortal Wkly Rep 2021; 70: 283.

20. Zhongming Z, Linong L, Wangqiang Z, et al. COVID-19 affects men and women differently. So why don’t clinical trials report gender data? Science 2021. http://resp.llas.ac.cn/C666/handle/2XK7JSWQ/333224

21. Hoffmann MA, Wieler HJ, Enders P, et al. Age- and sex-graded data evaluation of vaccination reactions after initial injection of the BNT162b2 mRNA vaccine in a local vaccination center in Germany. Vaccines (Basel) 2021; 9: 911.

22. Xiong X, Yuan J, Li M, et al. Age and gender disparities in adverse events following COVID-19 vaccination: real-world evidence based on big data for risk Management. Front Med (Lausanne) 2021; 8: 700014–700014.

23. Azimi M, Dehzaad WM, Atiq MA, et al. Adverse effects of the COVID-19 vaccine reported by Lecturers and Staff of Kabul University of Medical Sciences, Kabul, Afghanistan. Infect Drug Resist 2021; 14: 4077–4083.

24. Omeish H, Najadat A, Al-Azzam S, et al. Reported COVID-19 vaccines side effects among Jordanian population: a cross sectional study. Hum Vaccin Immunother 2022; 18: 1981086.

25. Solomon Y, Esthe T, Mekasha B, et al. COVID-19 vaccine: side effects after the first dose of the Oxford AstraZeneca vaccine among health professionals in low-income country: Ethiopia. J Multidiscip Healthc 2021; 14: 2577–2585.

26. Riad A, Sağiroğlu D, Üstün B, et al. Prevalence and risk factors of CoronaVac side effects: an independent cross-sectional study among healthcare workers in Turkey. J Clin Med 2021; 10: 2629.

27. Sultana A, Shahrain S, Talhsin MR, et al. A retrospective cross-sectional study assessing self-reported adverse events following immunization (AEFI) of the COVID-19 vaccine in Bangladesh. Vaccines (Basel) 2021; 9: 1090.

28. Alghamdi A, Ibrahim A, Almutairi R, et al. A cross-sectional survey of side effects after COVID-19 vaccination in Saudi Arabia: male versus female outcomes. J Adv Pharm Educ Res 2021; 11: 51–56.

29. Klein SL and Flanagan KL. Sex differences in immune responses. Nat Rev Immunol 2016; 16: 626–638.

30. Bouman A, Schipper M, Heineman MJ, et al. Gender difference in the non-specific and specific immune response in humans. Am J Reprod Immunol 2004; 52: 19–26.

31. Simon AK, Hollander GA and McMichael A. Evolution of the immune system in humans from infancy to old age. Proc Biol Sci 2015; 282: 20143085.

32. Sadighi Akha AA. Aging and the immune system: an overview. J Immunol Methods 2018; 463: 21–26.

33. Nahid P, Jarlsberg LG, Kato-Maeda M, et al. Interplay of strain and race/ethnicity in the innate immune response to M. tuberculosis. PLoS One 2018; 13: e0195392.